Search results
Added:
2 months ago
Lp(a) and Atherosclerosis
Added:
1 week ago
Review Article
Added:
4 months ago
TCT 2025 - The randomized VICTORY Study finds OCT-guided PCI involving lesion preparation with the OPN super-high-pressure non-compliant balloon is non-inferior to intravascular lithotropsy.Dr Matthias Bossard (Kantonsspital Lucerne, Lucerne, CH) joins us to discuss findings from the VICTORY Trial, a randomized, multicenter, non-inferiority comparison evaluating intravascular lithotripsy versus…
View more
Added:
2 days ago
Source:
Radcliffe CVRM
For patients with elevated lipoprotein(a) [Lp(a)] and established cardiovascular disease (CVD), weekly lipoprotein apheresis (LA) is the only approved treatment, but it represents a significant burden. The Lp(a)FRONTIERS APHERESIS trial investigated whether the investigational therapy pelacarsen could reduce the need for this invasive procedure.¹Mechanism of ActionPelacarsen is a hepatocyte…
View more
Added:
3 days ago
Source:
Radcliffe CVRM
For patients with heterozygous familial hypercholesterolemia (HeFH), achieving adequate low-density lipoprotein cholesterol (LDL-C) lowering remains a significant challenge. New results from the BROOKLYN trial suggest that the investigational agent obicetrapib could be an effective add-on therapy for this high-risk population.¹Mechanism of ActionObicetrapib is a highly selective cholesteryl ester…
View more
Added:
6 months ago
ESC Congress 2025 - Cascade screening proves to be an effective tool to identify more patients with elevated LP(a) levels.Dr Jonas Brinck (Karolinska Institute, SE) joins us to discuss findings from the LipoaScreen study, evaluating cascade screening for elevated lipoprotein(a) in relatives of patients with atherosclerotic coronary artery disease.This prospective study examined whether elevated…
View more
Added:
3 months ago
AHA Scientific Sessions 2025 - Dr Michelle O'Donoghue (Brigham and Women's Hospital, US) joins us to discuss the evolving understanding of the causal relationship between elevated lipoprotein(a) and atherosclerotic cardiovascular disease, and what this means for risk stratification and management strategies in clinical practice.Dr O'Donoghue begins by highlighting the importance for clinicians to…
View more
Added:
1 week ago
Source:
Radcliffe Cardiology
Written by Mirjam Boros, Radcliffe CardiologyA new oral proprotein convertase subtilisin–kexin type 9 (PCSK9) inhibitor, enlicitide, has demonstrated a significant reduction in low-density lipoprotein cholesterol (LDL-C) levels in patients with or at risk of atherosclerotic cardiovascular disease (ASCVD), according to results from the CORALreef Lipids trial.¹Mechanism of ActionEnlicitide is an…
View more
Added:
2 years ago
AHA 2023 — Investigator, Dr Steven E Nissen (Cleveland Clinic, US) is interviewed by CardioNerds Medical Education Fellow, Dr Maryam Barkhordarian (HMH Palisades Medical Center, US) on the trial that assessed the efficacy and safety of lepodisiran, a small interfering RNA (NCT05565742).The main purpose of this phase 2, randomised, double-blind, placebo-controlled study (Eli Lilly and Company) is…
View more
Added:
1 year ago
AHA Conference 2024 - Safety and efficacy outcomes of zerlasiran (Silence Therapeutics) in adults with elevated lipoprotein(a) at high risk of atherosclerotic cardiovascular disease events (ASCVD).Dr Steven Nissen (Cleveland Clinic, US) joins us onsite at AHA Conference to discuss the findings from ALPACAR (NCT05537571).ALPACAR is a phase 2, randomized, five-arm, placebo-controlled trial…
View more